Safety and Efficacy of Oral Belumosudil in Black or African American Male and Female Participants Aged 12 Years and Above With Chronic Graft Versus Host Disease (cGVHD) After At Least 2 Prior Lines of Systemic Therapy - NCT05567406

Number of participants with treatment emergent adverse events and serious adverse events, Number of participants with clinically significant laboratory abnormalities, Change from baseline in systolic and diastolic blood pressure, (and 18 more...)